Loading
Chidamide, approved in 2014, was the first epigenetic cancer drug invented in China and the first oral drug of its kind anywhere, used for T-cell lymphoma and, with hormone therapy, for breast cancer.
Chipscreen Biosciences' chidamide was approved by the CFDA in December 2014 for relapsed or refractory peripheral T-cell lymphoma, the first China-origin small molecule in a new chemical class and the first oral subtype-selective HDAC inhibitor approved anywhere. The ACE trial (Lancet Oncology 2019) added HR-positive advanced breast cancer with exemestane after endocrine therapy, approved in 2019. Licensed to HUYA Bioscience as HBI-8000, it was approved in Japan in 2021 for adult T-cell leukaemia-lymphoma and is being tested with PD-1 antibodies in melanoma.
Benzamide-class inhibitor of class I HDACs 1, 2 and 3 and class IIb HDAC10, relaxing chromatin, restoring tumour suppressor expression and enhancing NK and T-cell activity.
1.Tucidinostat (chidamide) slips into a pocket on its target.
Compare all products across the US, EU, UK, Japan, China and Australia →
| Region | Year | Indication |
|---|---|---|
| China | 2014 | Relapsed or refractory peripheral T-cell lymphoma |
| China | 2019 | HR-positive, HER2-negative advanced breast cancer with exemestane after endocrine therapy (ACE) |
| Japan | 2021 | Relapsed or refractory adult T-cell leukaemia-lymphoma (HBI-8000) |
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Tucidinostat" OR ABSTRACT:"Tucidinostat" OR TITLE:"chidamide" OR ABSTRACT:"chidamide" OR TITLE:"Epidaza" OR ABSTRACT:"Epidaza" OR TITLE:"HBI-8000" OR ABSTRACT:"HBI-8000" OR TITLE:"CS055" OR ABSTRACT:"CS055" OR TITLE:"Chidamide" OR ABSTRACT:"Chidamide") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Tucidinostat (chidamide), not a curated reading list.
Shares A Clinical Study on the Efficacy and Safety of Fruquintinib in Combination With PD-1 Monoclonal Antibody and Chidamide in Refractory MSS Metastatic Colorectal C, A Study of Tucidinostat in Combination With Sintilimab and Bevacizumab in MSS/pMMR Colorectal Cancer Patients, Safety and Efficacy of Fruquintinib Plus Chidamide and Sintilimab in the Third and Later Line Treatment of MSS/pMMR Metastatic Colorectal Cancer and the tag china.
Shares Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma) and the tag china.
Shares Clinical Study of Mitoxantrone Hydrochloride Liposome Injection vs. Chidamide in Patients With Relapsed/Refractory PTCL and the tag china.
Shares HR-positive / HER2-negative breast cancer and the tag china.
Shares HR-positive / HER2-negative breast cancer and the tag china.
Shares HR-positive / HER2-negative breast cancer and the tag china.
Shares QL1706 Plus Chidamide, AG as First-line Treatment for Metastatic Pancreatic Cancer and the tag china.
Shares Chipscreen Biosciences, Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma).